pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Kineret
drug
save

anakinra

Marketedupdated 5mo ago
by Sobi Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • tagApproval72 co-mentions · 18 sources
  • tagAsthma1 co-mentions · 1 sources

indications

investigational
Rheumatoid Arthritis

all catalysts(0)

nothing on the calendar yet

Trials studying anakinra

  • —Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infantsrecruitingn=1,600
  • phase2Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Diseaserecruitingn=57
  • phase2A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicitycompletedn=15
  • phase2Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapycompletedn=27
  • phase4A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMFnot yet recruitingn=3
  • phase3A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)active not recruitingn=15
  • phase2Open-label Study of Anakinra in MPS IIIcompletedn=24
  • —Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)completedn=306

News(0)

no news has mentioned this drug yet

brand
Kineret
generic
anakinra
indication
Neonatal Onset Multisystem Inflammatory Disease
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?